ClinicalTrials.gg
Not yet recruitingNCT07705997Updated Jul 15, 2026

Prospective Cohort Study of Aging in Patients With Acute Myocardial Infarction

An observational study in Acute Myocardial Infarction (AMI), sponsored by The Affiliated Hospital of Hangzhou Normal University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by The Affiliated Hospital of Hangzhou Normal University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Planned enrollment
57th of 89
600 · median 1,000
Started
2026
with 19 others
Observational
89 of 196
37 open now
Primary completion
2030-08
later than 63 of 72 live
Registered
191st of 196
by date

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 57th largest by planned enrollment of the 89 observational ones that give a count, is one of 20 that started in 2026, is one of 89 observational ones, reaches primary completion later than 63 of the 72 other live ones, and was the 191st registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.

03

Conditions studied

  • Acute Myocardial Infarction (AMI)
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes consecutively enrolled patients with acute myocardial infarction (AMI) and aging characteristics at a single center. Eligible participants will undergo standardized clinical assessment, aging evaluation, biospecimen collection, and prospective follow-up to investigate aging-related biomarkers and long-term clinical outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an form.

Exclusion criteria

Exclusion Criteria:

  • 1. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease/liver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients With Acute Myocardial Infarction and Aging Characteristics

    Patients with acute myocardial infarction (AMI) and aging characteristics who meet the eligibility criteria will be consecutively enrolled in this prospective observational cohort. Participants will undergo comprehensive clinical evaluation, aging assessment, laboratory testing, cardiac imaging, biospecimen collection, and standardized follow-up for at least 24 months to investigate aging-related biomarkers, clinical outcomes, and prognostic risk prediction.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events (MACE)

    The occurrence of major adverse cardiovascular events, including all-cause death, cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, stent restenosis or thrombosis, severe bleeding, and aging-related serious adverse events.

    Time frame: Baseline through 24 months of follow-up

Secondary outcomes

  1. All-cause mortality

    Death from any cause during follow-up.

    Time frame: Baseline through 24 months

  2. Cardiovascular mortality

    Death attributable to cardiovascular causes, including sudden cardiac death, heart failure, or cardiogenic shock.

    Time frame: Baseline through 24 months

  3. Hospitalization for heart failure

    Hospital admission due to worsening heart failure requiring intravenous diuretics, inotropic agents, or vasoactive therapy.

    Time frame: Baseline through 24 months

  4. Recurrent myocardial infarction

    New acute myocardial infarction occurring during follow-up according to standard diagnostic criteria.

    Time frame: Baseline through 24 months

  5. Aging-related serious adverse events

    Aging-related adverse outcomes, including cognitive decline, frailty-related fracture after low-energy falls, or loss of activities of daily living.

    Time frame: Baseline through 24 months

  6. Prognostic performance of the aging-related risk prediction model

    Predictive performance of the prognostic model integrating clinical characteristics, aging assessments, and aging-related biomarkers, evaluated using discrimination and calibration metrics.

    Time frame: At completion of the 24-month follow-up

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2030, 48 months later.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 48 months is below that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2030
CompletionEst.
Sep 1, 2030
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07705997
Lead sponsor
The Affiliated Hospital of Hangzhou Normal University
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Jul 15, 2026

Study contacts

Mingwei W Wang, PhD
Contact
wmw990556@163.com
18758871517 ext. not

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion